Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 125.9%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 6,100 shares, a growth of 125.9% from the November 30th total of 2,700 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 9,000 shares, the short-interest ratio is currently 0.7 days.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a research report on Thursday, December 19th.

Armata Pharmaceuticals Trading Up 4.5 %

Armata Pharmaceuticals stock opened at $2.11 on Friday. The firm has a market capitalization of $76.34 million, a price-to-earnings ratio of -1.29 and a beta of 0.78. Armata Pharmaceuticals has a fifty-two week low of $1.85 and a fifty-two week high of $4.48.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.